Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team.
Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B, Samson P, Staprans S, McNamara J, Moye J, Maddon PJ, Olson WC. Shearer WT, et al. Among authors: olson wc. J Infect Dis. 2000 Dec;182(6):1774-9. doi: 10.1086/317622. Epub 2000 Oct 27. J Infect Dis. 2000. PMID: 11069253 Clinical Trial.
Resistance to HIV-1 entry inhibitors.
Olson WC, Maddon PJ. Olson WC, et al. Curr Drug Targets Infect Disord. 2003 Dec;3(4):283-94. doi: 10.2174/1568005033481015. Curr Drug Targets Infect Disord. 2003. PMID: 14754430 Review.
Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
Shearer WT, DeVille JG, Samson PM, Moye JH Jr, Fletcher CV, Church JA, Spiegel HM, Palumbo P, Fenton T, Smith ME, Graham B, Kraimer JM, Olson WC. Shearer WT, et al. Among authors: olson wc. J Allergy Clin Immunol. 2006 Aug;118(2):518-21. doi: 10.1016/j.jaci.2006.03.028. Epub 2006 May 19. J Allergy Clin Immunol. 2006. PMID: 16890780 No abstract available.
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. Jacobson JM, et al. Among authors: olson wc. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9. doi: 10.1128/AAC.48.2.423-429.2004. Antimicrob Agents Chemother. 2004. PMID: 14742190 Free PMC article. Clinical Trial.
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC. Jacobson JM, et al. Among authors: olson wc. J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169. J Infect Dis. 2008. PMID: 18771406 Clinical Trial.
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC. Jacobson JM, et al. Among authors: olson wc. Antimicrob Agents Chemother. 2010 Oct;54(10):4137-42. doi: 10.1128/AAC.00086-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660677 Free PMC article. Clinical Trial.
155 results